Panacea Biotec Limited (BOM:531349)
India · Delayed Price · Currency is INR 349.45
-7.05 (-1.98%)
At close: Feb 13, 2026
Panacea Biotec Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Revenue | 6,056 | 5,591 | 5,592 | 4,599 | 6,612 | 6,248 |
Revenue Growth (YoY) | 7.56% | -0.01% | 21.57% | -30.44% | 5.83% | 14.84% |
Cost of Revenue | 2,562 | 1,995 | 2,301 | 2,527 | 2,622 | 2,046 |
Gross Profit | 3,494 | 3,596 | 3,290 | 2,073 | 3,990 | 4,202 |
Selling, General & Admin | 2,073 | 1,973 | 1,643 | 1,517 | 2,050 | 1,774 |
Other Operating Expenses | 1,684 | 1,804 | 1,695 | 1,192 | 1,987 | 1,544 |
Operating Expenses | 4,094 | 4,125 | 3,705 | 3,100 | 4,474 | 3,774 |
Operating Income | -599.68 | -529.78 | -414.69 | -1,027 | -484.18 | 427.33 |
Interest Expense | -49.32 | -29.22 | -26.73 | -38.03 | -1,798 | -1,847 |
Interest & Investment Income | 77.12 | 77.12 | 84.07 | 120.62 | 33.94 | 32.68 |
Earnings From Equity Investments | - | - | - | - | - | 0.77 |
Currency Exchange Gain (Loss) | 36.99 | 36.99 | 36.23 | 20.77 | 5.8 | -6.88 |
Other Non Operating Income (Expenses) | 13.26 | -9.54 | -9.08 | -6.34 | -10.02 | -6.45 |
EBT Excluding Unusual Items | -521.63 | -454.43 | -330.2 | -930.37 | -2,253 | -1,399 |
Gain (Loss) on Sale of Investments | 24.5 | 24.5 | 33.41 | 14.47 | 0.01 | - |
Gain (Loss) on Sale of Assets | 4.46 | 4.46 | -2.64 | 52.93 | 0.07 | -0.38 |
Asset Writedown | -13.95 | -13.95 | -46.14 | -29.94 | -15.75 | -42.63 |
Other Unusual Items | 445.04 | 359.94 | 360.34 | 1,021 | 16,762 | - |
Pretax Income | -61.58 | -79.48 | 14.77 | 128.05 | 14,494 | -1,442 |
Income Tax Expense | 19.91 | 7.71 | 29.82 | 465.5 | 3,710 | 19.57 |
Earnings From Continuing Operations | -81.49 | -87.19 | -15.05 | -337.45 | 10,783 | -1,462 |
Earnings From Discontinued Operations | - | - | - | - | - | -14.55 |
Net Income to Company | -81.49 | -87.19 | -15.05 | -337.45 | 10,783 | -1,477 |
Minority Interest in Earnings | 3.69 | 3.49 | 3.32 | 5.08 | -0.19 | -0.38 |
Net Income | -77.8 | -83.7 | -11.73 | -332.37 | 10,783 | -1,477 |
Net Income to Common | -77.8 | -83.7 | -11.73 | -332.37 | 10,783 | -1,477 |
Shares Outstanding (Basic) | 61 | 61 | 61 | 61 | 61 | 61 |
Shares Outstanding (Diluted) | 61 | 61 | 61 | 61 | 61 | 61 |
EPS (Basic) | -1.28 | -1.37 | -0.19 | -5.43 | 176.05 | -24.11 |
EPS (Diluted) | -1.28 | -1.37 | -0.19 | -5.43 | 176.05 | -24.11 |
Free Cash Flow | - | -776.74 | -794.08 | -4,634 | -1,210 | 848.87 |
Free Cash Flow Per Share | - | -12.68 | -12.96 | -75.66 | -19.75 | 13.86 |
Gross Margin | 57.70% | 64.31% | 58.85% | 45.07% | 60.35% | 67.25% |
Operating Margin | -9.90% | -9.48% | -7.42% | -22.34% | -7.32% | 6.84% |
Profit Margin | -1.29% | -1.50% | -0.21% | -7.23% | 163.08% | -23.64% |
Free Cash Flow Margin | - | -13.89% | -14.20% | -100.75% | -18.29% | 13.59% |
EBITDA | -292.34 | -207.64 | -72.82 | -641.24 | -56.28 | 872.65 |
EBITDA Margin | -4.83% | -3.71% | -1.30% | -13.94% | -0.85% | 13.97% |
D&A For EBITDA | 307.34 | 322.14 | 341.87 | 386.15 | 427.9 | 445.32 |
EBIT | -599.68 | -529.78 | -414.69 | -1,027 | -484.18 | 427.33 |
EBIT Margin | -9.90% | -9.48% | -7.42% | -22.34% | -7.32% | 6.84% |
Effective Tax Rate | - | - | 201.90% | 363.53% | 25.60% | - |
Revenue as Reported | 6,285 | 5,798 | 5,850 | 5,116 | 6,722 | 6,348 |
Advertising Expenses | - | 194.73 | 113.04 | 218.21 | 220.05 | 183.74 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.